Charles River Laboratories International, Inc announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification. Accugenix NGS simultaneously sequences millions of individual DNA fragments from a sample and provides key information to pharmaceutical and personal care manufacturers regarding microbial control.
When studying pure isolates and/or sequencing of mixed species environments, Accugenix NGS provides a deeper resolution of organism genes and variants at a level never before possible. The platform answers client questions, provides more robust compliance capabilities and higher levels of control, while offering partnership with a global network of labs, bioinformaticians, and specialists who interpret results and provide post-report support.
Enhancing Accugenix Global Availability
Charles River recently entered into partnerships with MPL – Mikrobiologisches Prüflabor (Austria) and Sure Laboratories (The Netherlands) to provide regional access to rapid, accurate microbial identifications to the industrial microbiology market, including pharmaceutical, biopharmaceutical, personal care and other global manufacturing industries. These agreements bring together Charles River’s curated, proprietary microbial identification database and the high-quality extensive testing services of international microbiological laboratories.
Customers of MPL and Sure Laboratories will now be able to leverage the robust Accugenix sequence and MALDI-TOF databases, consisting of relevant species that frequently occur in sterile and nonsterile manufacturing environments. Both databases are regularly updated to provide the most accurate and taxonomically correct identifications.
